ARXX Therapeutics ApS: Financial statements 2024
CVR: 40868151
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
ARXX Therapeutics ApS (CVR 40868151) has filed annual accounts for 2024. In 2024, the company reported revenue of DKK 2,608,206 and a net result of DKK 116,729 compared with DKK 269,759 the year before. That is a decrease of 6.5% compared with the year before. The profit margin was 4.5%. Equity in the 2024 report amounted to DKK 982,209. The solvency ratio was 72.7%.
- Revenue
- DKK 2,608,206
- Gross Profit
- DKK 2,332,814
- Profit/Loss
- DKK 116,729
- Equity
- DKK 982,209
- Total Assets
- DKK 1,351,396
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | 2.6M | 2.3M | 117K | 982K | - |
| 2023 | 2.8M | 1.9M | 270K | 865K | - |
| 2022 | 5.8M | 2.2M | 507K | 596K | - |
| 2021 | 2.4M | 1.7M | 77K | 177K | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
ARXX Therapeutics ApS has published its annual report for 2023. Revenue came to DKK 2,790,576, and the net result was DKK 269,759.
About ARXX Therapeutics ApS
ARXX Therapeutics ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2019. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Berte Aagot Hedding Poulsson and Jonas Hallén. The company is owned by ARXX THERAPEUTICS AS. The company has 2 employees (2026). In 2025, the company reported revenue of DKK 3,743,522 and a net result of DKK 706,595 compared with DKK 116,729 the year before. Equity in the 2025 report amounted to DKK 1,688,804.